Talquetamab represents the first-in-class BsAb targeting GPRC5D (G protein-coupled receptor of family C, group 5, member D) to have been explored in MM, starting from preclinical studies and subsequently in clinical trials. The gene discussed is GPRC5D; the disease is Miyoshi myopathy.